We revealed a novel angiogenesis-induced drug resistance mechanism and predicted a synergistic drug combination using an EGFR inhibitor and a VEGFR inhibitor targeting both tumor cells and angiogenesis, which was consistent with the experimental data. Here, EGFR is linked to neoplasm.